Pharmacogenetic significance of inosine triphosphatase

被引:77
作者
Bierau, Jorgen [1 ]
Lindhout, Martijn [1 ]
Bakker, Jaap A. [1 ]
机构
[1] Maastricht Univ Hosp, Lab Biochem Genet, Dept Clin Genet, Maastricht, Netherlands
关键词
adverse drug; reactions; allelic variant; azathioprine; inborn error of; metabolism; inosine; triphosphatase; triphosphate; pyrophosphohydrolase; mercaptopurine; pharmacogenetics; thiopurine; thiopurine methyltransferase;
D O I
10.2217/14622416.8.9.1221
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Inosine triphosphatase (ITPase) is the enzyme that catalyzes the conversion of inosine triphosphate (ITP) and deoxy-inosine triphosphate (dITP) to inosine monophosphate and deoxy-inosine monophosphate, respectively, thereby maintaining low intracellular concentrations of ITP and dITR Individuals deficient in ITPase activity were first recognized over 30 years ago. For decades, no clinical significance could be attributed to this inborn error of metabolism whatsoever. In recent years, evidence has started to accumulate that polymorphisms in the gene encoding ITPase are associated with potentially severe adverse drug reactions towards the thiopurine drugs azathioprine and 6-mercaptopurine. The pharmacogenetic significance is presently being debated in the literature. However, the present state of knowledge is still insufficient to definitively determine the pharmacogenetic significance of ITPase. This article aims to review the current knowledge on the role of ITPase in thiopurine metabolism.
引用
收藏
页码:1221 / 1228
页数:8
相关论文
共 41 条
  • [1] ITPA genotyping test does not improve detection of Crohn's disease patients at risk of azathioprine/6-mercaptopurine induced myelosuppression
    Allorge, D
    Hamdan, R
    Broly, F
    Libersa, C
    Colombel, JF
    [J]. GUT, 2005, 54 (04) : 565 - 565
  • [2] The ITPA c.94C>A and g.IVS2+21A>C sequence variants contribute to missplicing of the ITPA gene
    Arenas, Monica
    Duley, John
    Sumi, Satoshi
    Sanderson, Jeremy
    Marinaki, Anthony
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2007, 1772 (01): : 96 - 102
  • [3] Analysis of ITPA phenotype-genotype correlation in the Bulgarian population revealed a novel gene variant in Exon 6
    Atanasova, Srebrena
    Shipkova, Maria
    Svinarov, Dobrin
    Mladenova, Antoaneta
    Genova, Mariana
    Wieland, Eberhard
    Oellerich, Michael
    von Ahsen, Nicolas
    [J]. THERAPEUTIC DRUG MONITORING, 2007, 29 (01) : 6 - 10
  • [4] Relevance of pharmacogenetic aspects of mercaptopurine metabolism in the treatment of interstitial lung disease
    Bakker, Jaap A.
    Drent, Marjolein
    Bierau, Joergen
    [J]. CURRENT OPINION IN PULMONARY MEDICINE, 2007, 13 (05) : 458 - 463
  • [5] Determination of ITPase activity in erythrocyte lysates obtained for determination of TPMT activity
    Bierau, J.
    Bakker, J. A.
    Lindhout, M.
    van Gennip, A. H.
    [J]. NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2006, 25 (9-11) : 1129 - 1132
  • [6] Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation
    Breen, DP
    Marinaki, AM
    Arenas, M
    Hayes, PC
    [J]. LIVER TRANSPLANTATION, 2005, 11 (07) : 826 - 833
  • [7] DNA polymorphisms in ITPA including basis of inosine triphosphatase deficiency
    Cao, HN
    Hegele, RA
    [J]. JOURNAL OF HUMAN GENETICS, 2002, 47 (11) : 620 - 622
  • [8] Pharmacogenetics of thiopurine therapy in paediatric IBD patients
    De Ridder, L
    van Dieren, JM
    van Deventer, HJH
    Stokkers, PCF
    van der Woude, JCJ
    van Vuuren, AJ
    Benninga, MA
    Escher, JC
    Hommes, DW
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 23 (08) : 1137 - 1141
  • [9] Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease - Implications for therapy
    Derijks, LJJ
    Gilissen, LPL
    Engels, LGJB
    Bos, LP
    Bus, PJ
    Lohman, JJHM
    Curvers, WL
    van Deventer, SJH
    Hommes, DW
    Hooymans, PM
    [J]. THERAPEUTIC DRUG MONITORING, 2004, 26 (03) : 311 - 318
  • [10] Thiopurines in inflammatory bowel disease: New strategies for optimization of pharmacotherapy?
    Luc J. J. Derijks
    Daniel W. Hommes
    [J]. Current Gastroenterology Reports, 2006, 8 (2) : 89 - 92